Condition: Triple Negative Breast Cancer(TNBC) · Sponsor: Biotheus Inc.
This multicenter, randomized, double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally advanced/metastatic triple-negative breast cancer(TNBC)
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| The first affiliated hospital of bengbu medical University | Bengbu, Anhui, China | — |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | — |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | — |
| Fifth Medical Center of Chinese PLA General Hospital | Beijing, Beijing Municipality, China | — |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | — |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | — |
| The Southwest Hospital of Army Medical University | Chongqing, Chongqing Municipality, China | — |
| Fujian Provincial Cancer Hospital | Fuzhou, Fujian, China | — |
| Lanzhou University First Hospital | Lanzhou, Gansu, China | — |
| The First People's Hospital of Foshan | Foshan, Guangdong, China | — |
| Affillated Cancer Hospital and Institute of Guangzhou Medical University | Guangzhou, Guangdong, China | — |
| Sun Yat-sen Memorial Hospital Affiliated to Sun Yat-sen University | Guangzhou, Guangdong, China | — |
+ 58 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06419621